

Michael C Jensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1186023/publications.pdf>

Version: 2024-02-01

75
papers

16,294
citations

71102

41
h-index

88630

70
g-index

77
all docs

77
docs citations

77
times ranked

12884
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 21-29.	1.2	31
2	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 999-1009.	4.1	8
3	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. <i>Cancer Immunology Research</i> , 2022, 10, 856-870.	3.4	7
4	Optimized serum stability and specificity of an α CD26 integrin-binding peptide for tumor targeting. <i>Journal of Biological Chemistry</i> , 2021, 296, 100657.	3.4	7
5	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. <i>Cancers</i> , 2021, 13, 1050.	3.7	17
6	IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS. <i>Neuro-Oncology</i> , 2021, 23, i29-i29.	1.2	7
7	Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. <i>Cancer Immunology Research</i> , 2021, 9, 1047-1060.	3.4	6
8	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 1544-1552.	30.7	138
9	Arming Immune Cell Therapeutics with Polymeric Prodrugs. <i>Advanced Healthcare Materials</i> , 2021, , 2101944.	7.6	1
10	Biomaterials in Chimeric Antigen Receptor T-Cell Process Development. <i>Accounts of Chemical Research</i> , 2020, 53, 1724-1738.	15.6	23
11	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	4.8	20
12	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , 2019, 19, 895.	2.6	40
13	Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy. <i>Nature Biomedical Engineering</i> , 2019, 3, 783-795.	22.5	56
14	Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cryopreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 223-232.	2.0	17
15	Cell-templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen-presenting Cells for T Cell Activation. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801188.	7.6	38
16	CD19 CAR T cell product and disease attributes predict leukemia remission durability. <i>Journal of Clinical Investigation</i> , 2019, 129, 2123-2132.	8.2	244
17	Novel CD19 ^{hi} T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo. <i>Blood</i> , 2019, 134, 223-223.	1.4	15
18	Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses. <i>Blood</i> , 2019, 134, 3869-3869.	1.4	10

#	ARTICLE	IF	CITATIONS
19	EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. <i>Oncotarget</i> , 2019, 10, 7080-7095.	1.8	52
20	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. <i>Molecular Therapy</i> , 2018, 26, 280-288.	8.2	76
21	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. <i>Molecular Therapy</i> , 2018, 26, 1423-1434.	8.2	37
22	Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy. <i>Blood</i> , 2018, 132, 4012-4012.	1.4	4
23	Novel CD19 ⁺ T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety. <i>Blood</i> , 2018, 132, 4021-4021.	1.4	2
24	Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells. <i>Blood</i> , 2018, 132, 2957-2957.	1.4	9
25	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i100-i101.	1.2	0
26	Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility. <i>Clinical Cancer Research</i> , 2017, 23, 466-477.	7.0	81
27	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. <i>Blood</i> , 2017, 129, 3322-3331.	1.4	861
28	CD19 CAR ⁺ T cells of defined CD4 ⁺ :CD8 ⁺ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , 2016, 126, 2123-2138.	8.2	1,657
29	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. <i>PLoS ONE</i> , 2016, 11, e0146885.	2.5	34
30	ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. <i>Cancer Immunology Research</i> , 2016, 4, 639-641.	3.4	23
31	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 2561-2569.	27.0	1,326
32	T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. <i>Cancer Immunology Research</i> , 2016, 4, 498-508.	3.4	456
33	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , 2016, 127, 2406-2410.	1.4	622
34	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nature Communications</i> , 2016, 7, 12320.	12.8	325
35	Comparison of naïve and central memory derived CD8 ⁺ effector cell engraftment fitness and function following adoptive transfer. <i>OncImmunology</i> , 2016, 5, e1072671.	4.6	25
36	Bioactivity and Safety of IL13R ⁺ 2-Redirected Chimeric Antigen Receptor CD8 ⁺ T Cells in Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 4062-4072.	7.0	573

#	ARTICLE	IF	CITATIONS
37	Designing chimeric antigen receptors to effectively and safely target tumors. <i>Current Opinion in Immunology</i> , 2015, 33, 9-15.	5.5	158
38	Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell FasL-Dependent AICD. <i>Cancer Immunology Research</i> , 2015, 3, 368-379.	3.4	144
39	Multiplexed gene transfer to a human T cell line by combining Sleeping Beauty transposon system with methotrexate selection. <i>Biotechnology and Bioengineering</i> , 2015, 112, 1429-1436.	3.3	10
40	Synthetic immunobiology boosts the IQ of T cells. <i>Science</i> , 2015, 350, 514-515.	12.6	9
41	The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for <i>In Vivo</i> Antitumor Activity. <i>Cancer Immunology Research</i> , 2015, 3, 125-135.	3.4	406
42	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves <i>In Vivo</i> Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , 2015, 126, 184-184.	1.4	49
43	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves <i>In Vivo</i> Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3773-3773.	1.4	39
44	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. <i>Immunological Reviews</i> , 2014, 257, 127-144.	6.0	134
45	Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes. <i>Journal of Immunotherapy</i> , 2014, 37, 93-104.	2.4	50
46	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	1.4	2,080
47	Chimeric β 2-microglobulin cytokine receptors confer cytokine independent engraftment of human T lymphocytes. <i>Molecular Immunology</i> , 2013, 56, 1-11.	2.2	12
48	Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 3153-3164.	7.0	441
49	Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. <i>PLoS ONE</i> , 2013, 8, e82742.	2.5	167
50	Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence. <i>Blood</i> , 2013, 122, SCI-39-SCI-39.	1.4	2
51	Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an <i>In Vivo</i> Cell Selection Strategy. <i>PLoS ONE</i> , 2013, 8, e65519.	2.5	25
52	Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. <i>Journal of Immunotherapy</i> , 2012, 35, 689-701.	2.4	128
53	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. <i>Blood</i> , 2012, 119, 72-82.	1.4	186
54	Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. <i>Molecular Immunology</i> , 2012, 51, 263-272.	2.2	158

#	ARTICLE	IF	CITATIONS
55	Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. <i>Blood</i> , 2011, 117, 1888-1898.	1.4	151
56	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. <i>Blood</i> , 2011, 118, 1255-1263.	1.4	496
57	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. <i>Blood</i> , 2010, 116, 4532-4541.	1.4	221
58	Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8531-8536.	7.1	238
59	Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1245-1256.	2.0	466
60	Adoptive transfer of virus-specific and tumor-specific T cell immunity. <i>Current Opinion in Immunology</i> , 2009, 21, 224-232.	5.5	59
61	Engineering GVL Through T Cell Gene Transfer. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 5.	2.0	0
62	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane. <i>Journal of Immunology</i> , 2008, 180, 7028-7038.	0.8	211
63	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. <i>Blood</i> , 2008, 112, 2261-2271.	1.4	628
64	Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. <i>Journal of Clinical Investigation</i> , 2008, 118, 294-305.	8.2	735
65	Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains. <i>Human Gene Therapy</i> , 2007, 18, 712-725.	2.7	199
66	Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells. <i>Journal of Immunology</i> , 2007, 179, 3332-3341.	0.8	133
67	Medulloblastomas Expressing IL13R α 2 are Targets for IL13-zetakine+ Cytolytic T Cells. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 669-677.	0.6	37
68	Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. <i>Molecular Therapy</i> , 2007, 15, 825-833.	8.2	531
69	CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. <i>Cancer Research</i> , 2006, 66, 10995-11004.	0.9	435
70	CD28-Costimulation Provided through a CD19-Specific Chimeric Immunoreceptor Enhances In Vivo Persistence and Anti-Tumor Efficacy of Adoptively Transferred T Cells.. <i>Blood</i> , 2005, 106, 1278-1278.	1.4	18
71	Development of a Nonhuman Primate Model for Analysis of the Adoptive Transfer of Antigen-Specific T Cell Clones.. <i>Blood</i> , 2005, 106, 770-770.	1.4	0
72	Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. <i>Cancer Research</i> , 2004, 64, 9160-9166.	0.9	342

#	ARTICLE	IF	CITATIONS
73	IL15, but Not IL2, Supports Long-Term Survival and Function of Human and Macaque Antigen-Specific CD8+ T Cell Clones.. Blood, 2004, 104, 3237-3237.	1.4	0
74	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B α lineage leukemia effect. Blood, 2003, 101, 1637-1644.	1.4	245
75	Human T Lymphocyte Genetic Modification with Naked DNA. Molecular Therapy, 2000, 1, 49-55.	8.2	102